Galmed Pharmaceutica (GLMD)

May 27, 2025, 8:00 AM EDT - 9 days ago

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

May 22, 2025, 8:00 AM EDT - 14 days ago

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 7:30 AM EDT - 4 weeks ago

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Apr 28, 2025, 8:00 AM EDT - 5 weeks ago

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Apr 17, 2025, 8:30 AM EDT - 7 weeks ago

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Apr 15, 2025, 8:30 AM EDT - 7 weeks ago

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Apr 10, 2025, 8:00 AM EDT - 2 months ago

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Apr 2, 2025, 4:10 PM EDT - 2 months ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Mar 20, 2025, 8:55 AM EDT - 2 months ago

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Sep 25, 2024, 8:00 AM EDT - 9 months ago

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Sep 19, 2024, 7:00 AM EDT - 9 months ago

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Apr 4, 2024, 5:06 PM EDT - 1 year ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Mar 15, 2024, 9:00 AM EDT - 1 year ago

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Nov 20, 2023, 4:32 PM EST - 1 year ago

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Sep 26, 2023, 8:30 AM EDT - 1 year ago

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Sep 22, 2023, 4:05 PM EDT - 1 year ago

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Jul 14, 2023, 9:30 AM EDT - 2 years ago

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

May 9, 2023, 7:00 AM EDT - 2 years ago

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

Mar 29, 2023, 5:00 PM EDT - 2 years ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Feb 8, 2023, 8:00 AM EST - 2 years ago

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Dec 14, 2022, 5:00 PM EST - 2 years ago

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Aug 4, 2022, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Jul 7, 2022, 8:27 AM EDT - 3 years ago

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

May 17, 2022, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

May 17, 2022, 7:30 AM EDT - 3 years ago

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

May 2, 2022, 1:56 PM EDT - 3 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call Transcript

May 2, 2022, 7:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

Apr 28, 2022, 7:00 AM EDT - 3 years ago

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Apr 26, 2022, 8:30 AM EDT - 3 years ago

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Jan 11, 2022, 7:30 AM EST - 3 years ago

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Jan 10, 2022, 9:14 AM EST - 3 years ago

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Jan 10, 2022, 7:30 AM EST - 3 years ago

Galmed announces positive results of Phase 1 study of Amilo-5MER

Nov 8, 2021, 3:24 PM EST - 3 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript

Nov 8, 2021, 7:30 AM EST - 3 years ago

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Nov 8, 2021, 7:00 AM EST - 3 years ago

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement

Nov 1, 2021, 10:10 AM EDT - 3 years ago

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study

Oct 11, 2021, 8:00 AM EDT - 3 years ago

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Aug 19, 2021, 11:49 AM EDT - 4 years ago

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action

Aug 19, 2021, 8:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound

Aug 16, 2021, 8:00 AM EDT - 4 years ago

MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study

Aug 9, 2021, 11:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call Transcript

Aug 5, 2021, 7:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

Aug 2, 2021, 9:26 AM EDT - 4 years ago

Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial

Aug 2, 2021, 7:30 AM EDT - 4 years ago

FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study

Jul 29, 2021, 8:30 AM EDT - 4 years ago

Galmed Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Business Update on Thursday August 5

May 13, 2021, 6:58 PM EDT - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2021 Results - Earnings Call Transcript

May 13, 2021, 7:50 AM EDT - 4 years ago

Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results

May 10, 2021, 2:00 AM EDT - 4 years ago

Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines

ONC NVAX